Abstract Library

#4513 Predictive value of different PD-L1 immunohistochemistry clones for immunotherapy efficacy in neuroendocrine tumours: A case series

Introduction: In the ZS001 clinical trial, we observed that NET patients with higher PD-L1 expression levels were more likely to benefit preferentially from immunotherapy.

Conference:

Presenting Author:

Authors: Sun Y, Zhang Q, Cao F, Huang X, Zhang P,

Keywords: neuroendocrine tumour, immunotherapy, PD-L1, SP142, 28-8, C0148, E1L3N,

#4481 Predicting peptide receptor radionuclide therapy (PRRT) response through the landscape of the immune microenvironment in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) often have poor prognosis upon metastasis. Peptide receptor radionuclide therapy (PRRT) is a novel treatment leveraging targeted cytotoxicity of radionuclides to efficiently address primary and metastatic tumours of NETs.

Conference:

Presenting Author: Yu J

Authors: Zeng Z, Lu M, Xie Q, Li J, Yang Z,

Keywords: peptide receptor radionuclide therapy, neuroendocrine tumour, tumour immune microenvironment, tumour response, therapeutic effect prediction,

#4421 Head-to-head comparison of 18F-AlF-NOTA-JR11 PET/MR and 68Ga-DOTATATE PET/CT in patients with neuroendocrine tumours: A prospective study

Introduction: PET/MR combines the molecular advantages of PET with excellent morphologic and anatomic delineation of MRI.18F-AlF-NOTA-JR11, a novel SSTR antagonist with a high affinity for SSTR2, has the potential to perform better than SSTR agonists in neuroendocrine tumour imaging.

Conference:

Presenting Author: Yu J

Authors: Jin X, Xie Q, Lu M, Li J, Yang Z,

Keywords: neuroendocrine tumour, PET/MR, SSTR antagonist, 18F-AlF-NOTA-JR11,

#4414 Impact of chromogranin A expression on clinicopathological characteristics and prognosis in patients with gastrointestinal tumours exhibiting neuroendocrine differentiation

Introduction: Pathological diagnosis of neuroendocrine differentiation (NED) relies on histomorphological assessment and specific markers, including chromogranin A (CgA) and synaptophysin (Syn). Previous studies indicate that tumours with a high proportion of CgA (+) exhibit increased malignancy and aggressiveness in neuroendocrine tumours, suggesting that CgA may serve as a prognostic marker.

Conference:

Presenting Author: Liang T

Authors: Wang W, Jiang K, Liu X, Zhao L, Yu Z,

Keywords: neuroendocrine differentiation, gastric cancer, colorectal cancer, chromogranin A,

#4381 TOPK promotes tumorigenesis and metastasis of pancreatic neuroendocrine neoplasms by enhancing the MAPK signalling pathway

Introduction: T-LAK cell-originated protein kinase (TOPK) is highly expressed in pancreatic neuroendocrine neoplasms (pNENs) with liver metastasis and is associated with a poor prognosis.

Conference:

Presenting Author: Chen Q

Authors: Chen Q, Yuan M, Meng M, Ren S, Li G,

Keywords: TOPK, Pancreatic Neuroendocrine Neoplasm, MAPK signalling pathway, Invasion and metastasis, HI-TOPK-032,